Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 30 October 2017 | By Michael Mezher
The European Medicines Agency (EMA) on Monday issued two draft revised guidelines on plasma-derived and recombinant coagulation factor VIII products that remove requirements for conducting clinical studies in previously untreated patients (PUPs).
Factor VIII products are used to treat or prevent bleeding in patients with hemophilia A (congenital factor VIII deficiency). The development of inhibitor antibodies is one of the greatest potential complications involved with treating patients with hemophilia A. When these antibodies appear, they can make factor VIII medicines less effective at controlling bleeding.
According to EMA, inhibitors occur in about 30% of PUPs with severe hemophilia A, typically within 100 days of treatment.
EMA says the two guidelines, one detailing the clinical requirements for supporting the marketing authorization of factor VIII products and the other describing the information that should be included in the summary of product characteristics (SmPC) for those products, are being revised to reflect the difficulty of conducting formal clinical studies in PUPs.
Under the previous versions of the guidelines, EMA required clinical studies in PUPs for all novel recombinant factor VIII products and for factor VIII products made using new production methods. EMA also required PUP studies on a case-by-case basis for plasma-derived factor VIII products.
"In light of increasing scientific knowledge, the number of suitable patients especially previously untreated patients (PUPs) to be enrolled in clinical trials is problematic," EMA writes.
As such, EMA says that sponsors will no longer be required to conduct formal clinical trials in previously untreated patients, and instead will be required to monitor previously untreated patients "through a well-defined and well-managed disease registry."
Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products
Guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products
Tags: Hemophilia, Factor VIII, Draft Guideline